File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: A double-blind, placebo-controlled trial
  • Basic View
  • Metadata View
  • XML View
TitleEffect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: A double-blind, placebo-controlled trial
 
AuthorsLai, KC1
Lau, CS1
Ip, WY1
Wong, BCY1
Hui, WM1
Hu, WHC1
Wong, RWM1
Lam, SK1
 
Issue Date2003
 
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
 
CitationAlimentary Pharmacology And Therapeutics, 2003, v. 17 n. 6, p. 799-805 [How to Cite?]
DOI: http://dx.doi.org/10.1046/j.1365-2036.2003.01528.x
 
AbstractBackground: There is controversy as to whether Helicobacter pylori and non-steroidal anti-inflammatory drugs interact to cause peptic ulcers. Aim: To study whether the eradication of H. pylori in patients on long-term non-steroidal anti-inflammatory drug therapy prevents the development of ulcers. Methods: Patients infected with H. pylori whilst receiving long-term non-steroidal anti-inflammatory drug therapy, but with no ulcers at baseline endoscopy, were randomized to receive either triple antibiotic therapy (metronidazole 300 mg, clarithromycin 250 mg and amoxicillin 500 mg, given four times daily: n = 70) or placebo (n = 70) for 2 weeks. Non-steroidal anti-inflammatory drugs were continued throughout the study period. Endoscopy was repeated 12 weeks after the end of treatment. The development of ulcers was compared between the two groups. Results: Endoscopy at 12 weeks revealed peptic ulcer development in five [7%; 95% confidence interval (CI), 2-16] of the patients who received triple therapy and in six (9%; 95% CI, 3-18) of those who received placebo (P = 1.00). No significant difference in the development of ulcers was found between patients with persistent H. pylori infection (7/80; 9%; 95% CI, 4-17) and those with the eradication of H. pylori (4/52; 8%; 95% CI, 2-19) (P = 1.00). Conclusions: The eradication of H. pylori in patients receiving long-term treatment with non-steroidal anti-inflammatory drugs did not prevent ulcer development. However, because the rate of ulcer development was low, a study with a larger sample size is required to confirm this finding.
 
ISSN0269-2813
2013 Impact Factor: 5.478
2013 SCImago Journal Rankings: 2.609
 
DOIhttp://dx.doi.org/10.1046/j.1365-2036.2003.01528.x
 
ISI Accession Number IDWOS:000181634100007
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorLai, KC
 
dc.contributor.authorLau, CS
 
dc.contributor.authorIp, WY
 
dc.contributor.authorWong, BCY
 
dc.contributor.authorHui, WM
 
dc.contributor.authorHu, WHC
 
dc.contributor.authorWong, RWM
 
dc.contributor.authorLam, SK
 
dc.date.accessioned2010-09-17T10:21:44Z
 
dc.date.available2010-09-17T10:21:44Z
 
dc.date.issued2003
 
dc.description.abstractBackground: There is controversy as to whether Helicobacter pylori and non-steroidal anti-inflammatory drugs interact to cause peptic ulcers. Aim: To study whether the eradication of H. pylori in patients on long-term non-steroidal anti-inflammatory drug therapy prevents the development of ulcers. Methods: Patients infected with H. pylori whilst receiving long-term non-steroidal anti-inflammatory drug therapy, but with no ulcers at baseline endoscopy, were randomized to receive either triple antibiotic therapy (metronidazole 300 mg, clarithromycin 250 mg and amoxicillin 500 mg, given four times daily: n = 70) or placebo (n = 70) for 2 weeks. Non-steroidal anti-inflammatory drugs were continued throughout the study period. Endoscopy was repeated 12 weeks after the end of treatment. The development of ulcers was compared between the two groups. Results: Endoscopy at 12 weeks revealed peptic ulcer development in five [7%; 95% confidence interval (CI), 2-16] of the patients who received triple therapy and in six (9%; 95% CI, 3-18) of those who received placebo (P = 1.00). No significant difference in the development of ulcers was found between patients with persistent H. pylori infection (7/80; 9%; 95% CI, 4-17) and those with the eradication of H. pylori (4/52; 8%; 95% CI, 2-19) (P = 1.00). Conclusions: The eradication of H. pylori in patients receiving long-term treatment with non-steroidal anti-inflammatory drugs did not prevent ulcer development. However, because the rate of ulcer development was low, a study with a larger sample size is required to confirm this finding.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationAlimentary Pharmacology And Therapeutics, 2003, v. 17 n. 6, p. 799-805 [How to Cite?]
DOI: http://dx.doi.org/10.1046/j.1365-2036.2003.01528.x
 
dc.identifier.doihttp://dx.doi.org/10.1046/j.1365-2036.2003.01528.x
 
dc.identifier.epage805
 
dc.identifier.hkuros81290
 
dc.identifier.isiWOS:000181634100007
 
dc.identifier.issn0269-2813
2013 Impact Factor: 5.478
2013 SCImago Journal Rankings: 2.609
 
dc.identifier.issue6
 
dc.identifier.pmid12641502
 
dc.identifier.scopuseid_2-s2.0-0037444981
 
dc.identifier.spage799
 
dc.identifier.urihttp://hdl.handle.net/10722/91583
 
dc.identifier.volume17
 
dc.languageeng
 
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofAlimentary Pharmacology and Therapeutics
 
dc.relation.referencesReferences in Scopus
 
dc.rightsAlimentary Pharmacology and Therapeutics. Copyright © Blackwell Publishing Ltd.
 
dc.subject.meshAdolescent
 
dc.subject.meshAdult
 
dc.subject.meshAged
 
dc.subject.meshAged, 80 and over
 
dc.subject.meshAmoxicillin - therapeutic use
 
dc.subject.meshAnti-Inflammatory Agents, Non-Steroidal - therapeutic use
 
dc.subject.meshClarithromycin - therapeutic use
 
dc.subject.meshDouble-Blind Method
 
dc.subject.meshDrug Therapy, Combination - therapeutic use
 
dc.subject.meshDuodenal Ulcer - prevention & control
 
dc.subject.meshDyspepsia - etiology
 
dc.subject.meshEndoscopy, Gastrointestinal
 
dc.subject.meshFemale
 
dc.subject.meshFollow-Up Studies
 
dc.subject.meshHelicobacter Infections - drug therapy
 
dc.subject.meshHelicobacter pylori
 
dc.subject.meshHumans
 
dc.subject.meshMale
 
dc.subject.meshMetronidazole - therapeutic use
 
dc.subject.meshMiddle Aged
 
dc.subject.meshStomach Ulcer - prevention & control
 
dc.titleEffect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: A double-blind, placebo-controlled trial
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Lai, KC</contributor.author>
<contributor.author>Lau, CS</contributor.author>
<contributor.author>Ip, WY</contributor.author>
<contributor.author>Wong, BCY</contributor.author>
<contributor.author>Hui, WM</contributor.author>
<contributor.author>Hu, WHC</contributor.author>
<contributor.author>Wong, RWM</contributor.author>
<contributor.author>Lam, SK</contributor.author>
<date.accessioned>2010-09-17T10:21:44Z</date.accessioned>
<date.available>2010-09-17T10:21:44Z</date.available>
<date.issued>2003</date.issued>
<identifier.citation>Alimentary Pharmacology And Therapeutics, 2003, v. 17 n. 6, p. 799-805</identifier.citation>
<identifier.issn>0269-2813</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/91583</identifier.uri>
<description.abstract>Background: There is controversy as to whether Helicobacter pylori and non-steroidal anti-inflammatory drugs interact to cause peptic ulcers. Aim: To study whether the eradication of H. pylori in patients on long-term non-steroidal anti-inflammatory drug therapy prevents the development of ulcers. Methods: Patients infected with H. pylori whilst receiving long-term non-steroidal anti-inflammatory drug therapy, but with no ulcers at baseline endoscopy, were randomized to receive either triple antibiotic therapy (metronidazole 300 mg, clarithromycin 250 mg and amoxicillin 500 mg, given four times daily: n = 70) or placebo (n = 70) for 2 weeks. Non-steroidal anti-inflammatory drugs were continued throughout the study period. Endoscopy was repeated 12 weeks after the end of treatment. The development of ulcers was compared between the two groups. Results: Endoscopy at 12 weeks revealed peptic ulcer development in five [7%; 95% confidence interval (CI), 2-16] of the patients who received triple therapy and in six (9%; 95% CI, 3-18) of those who received placebo (P = 1.00). No significant difference in the development of ulcers was found between patients with persistent H. pylori infection (7/80; 9%; 95% CI, 4-17) and those with the eradication of H. pylori (4/52; 8%; 95% CI, 2-19) (P = 1.00). Conclusions: The eradication of H. pylori in patients receiving long-term treatment with non-steroidal anti-inflammatory drugs did not prevent ulcer development. However, because the rate of ulcer development was low, a study with a larger sample size is required to confirm this finding.</description.abstract>
<language>eng</language>
<publisher>Blackwell Publishing Ltd. The Journal&apos;s web site is located at http://www.blackwellpublishing.com/journals/APT</publisher>
<relation.ispartof>Alimentary Pharmacology and Therapeutics</relation.ispartof>
<rights>Alimentary Pharmacology and Therapeutics. Copyright &#169; Blackwell Publishing Ltd.</rights>
<subject.mesh>Adolescent</subject.mesh>
<subject.mesh>Adult</subject.mesh>
<subject.mesh>Aged</subject.mesh>
<subject.mesh>Aged, 80 and over</subject.mesh>
<subject.mesh>Amoxicillin - therapeutic use</subject.mesh>
<subject.mesh>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject.mesh>
<subject.mesh>Clarithromycin - therapeutic use</subject.mesh>
<subject.mesh>Double-Blind Method</subject.mesh>
<subject.mesh>Drug Therapy, Combination - therapeutic use</subject.mesh>
<subject.mesh>Duodenal Ulcer - prevention &amp; control</subject.mesh>
<subject.mesh>Dyspepsia - etiology</subject.mesh>
<subject.mesh>Endoscopy, Gastrointestinal</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Follow-Up Studies</subject.mesh>
<subject.mesh>Helicobacter Infections - drug therapy</subject.mesh>
<subject.mesh>Helicobacter pylori</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Male</subject.mesh>
<subject.mesh>Metronidazole - therapeutic use</subject.mesh>
<subject.mesh>Middle Aged</subject.mesh>
<subject.mesh>Stomach Ulcer - prevention &amp; control</subject.mesh>
<title>Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: A double-blind, placebo-controlled trial</title>
<type>Article</type>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1046/j.1365-2036.2003.01528.x</identifier.doi>
<identifier.pmid>12641502</identifier.pmid>
<identifier.scopus>eid_2-s2.0-0037444981</identifier.scopus>
<identifier.hkuros>81290</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-0037444981&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>17</identifier.volume>
<identifier.issue>6</identifier.issue>
<identifier.spage>799</identifier.spage>
<identifier.epage>805</identifier.epage>
<identifier.isi>WOS:000181634100007</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong